FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of January 2026
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca invests $15bn in China through 2030
29 January
2026
AstraZeneca plans to invest $15 billion in China through 2030 to
pioneer the next-generation of innovative medicines
Landmark investment will expand AstraZeneca's capabilities to
discover, develop, and manufacture transformative new treatments in
China
Investment will support delivery of AstraZeneca's 2030
ambition
AstraZeneca today announced $15 billion investment in China through
2030 to expand medicines manufacturing and R&D. This investment
will leverage the country's scientific excellence, advanced
manufacturing, and China-UK healthcare ecosystem collaborations to
deliver cutting-edge treatments to patients across China and
globally.
Keir Starmer, UK Prime Minister, said: "Unlocking opportunities for
British businesses across the globe and delivering for working
people back home is always the driving force behind my
international engagements. AstraZeneca's expansion and leadership
in China will help the British manufacturer continue to grow -
supporting thousands of UK jobs. The multi-billion pound investment
announced today from AstraZeneca, alongside partnerships from some
of our country's leading universities, furthers research and
development in the UK which is helping to power our world class
life sciences sector."
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Today's
landmark investment of $15 billion begins an exciting next chapter
for AstraZeneca in China, which has become a critical contributor
to scientific innovation, advanced manufacturing, and global public
health. By expanding our capabilities in breakthrough treatments
like cell therapy and radioconjugates, we will strengthen our
contribution to China's high-quality development and, most
importantly, bring next-generation modalities to
patients."
Recognising China's advanced science in new modalities, this
investment will significantly enhance the Company's cell therapy
and radioconjugates capabilities that are driving its broad and
varied pipeline to help patients with cancer, haematological
conditions and autoimmune diseases, among others. These investments
span the value chain, from drug discovery and clinical development
to manufacturing, and bring Chinese innovation to the world through
our partnerships with leading biotechs including AbelZeta, CSPC,
Harbour BioMed, Jacobio and Syneron Bio. Building on the 2024
acquisition of Gracell Biotechnologies, AstraZeneca will also
become the first global biopharmaceutical leader with end-to-end
cell therapy capabilities in China.
These investments build on AstraZeneca's substantial R&D
footprint, including global strategic R&D centres in Beijing
and Shanghai, which collaborate with over 500 clinical hospitals,
and have led on a large number of global clinical trials in the
past three years alone. The Company will also develop its existing
manufacturing facilities in Wuxi, Taizhou, Qingdao, and Beijing,
which provide high-quality medicines to patients in China and 70
markets worldwide, together with the establishment of new sites to
be announced. Together, these investments will grow the Company's
highly skilled workforce in China beyond 20,000 and create
thousands of additional jobs across the healthcare
ecosystem.
The investment, announced during the UK Prime Minister's visit to
China, will strengthen China-UK collaboration in healthcare
innovation and will benefit the life sciences ecosystems of both
countries. Building on its successful ecosystem collaboration with
the University of Cambridge and Beijing, AstraZeneca is working
with other pre-eminent research and financial institutions -
including the University of Oxford, the University of Glasgow,
King's College London, and HSBC - to establish further
collaborations between dynamic ecosystems in both
countries.
This investment is fully aligned with the goals of Healthy China
2030 and will prioritise delivery of China's 'Common Health'
agenda, to expand prevention, early detection, and access to
innovative medicines for underserved communities.
Notes
AstraZeneca in China
China is AstraZeneca's second-largest market and a strategic hub
for global innovation, home to two global R&D centres that have
led 20 global clinical trials to-date, four manufacturing sites
that supply high-quality medicines to over 70 markets, and
commercial operations across five regional hubs. Headquartered in
Shanghai, AstraZeneca employs over 17,000 people in China and,
since 2023, has signed 16 global licensing agreements with 15
Chinese partners. Since entering China in 1993, AstraZeneca has
introduced over 40 innovative medicines, focusing on disease areas
such as oncology, respiratory, cardiovascular, renal &
metabolic, gastrointestinal, rare disease, and vaccines and
immunology. The Company's innovative medicines benefited 68 million
patients in China in 2025 alone.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on Social Media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date: 29 January 2026
|
|
By: /s/
Matthew Bowden
|
|
|
Name:
Matthew Bowden
|
|
|
Title:
Company Secretary
|